The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on.
INVENTIVA: Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Daix , Long Island City , April 3, 2024 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic.
INVENTIVA: Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.